Background: Functional movement disorders (FMDs), part of the wide spectrum of functional neurological disorders (conversion disorders), are common and often associated with a poor prognosis. Nevertheless, little is known about their neurobiological underpinnings, particularly with regard to the contribution of genetic factors. Because FMD and stress-related disorders share a common core of biobehavioural manifestations, we investigated whether variants in stress-related genes also contributed, directly and interactively with childhood trauma, to the clinical and circuit-level phenotypes of FMD.Methods: Sixty-nine patients with a ‘clinically defined’ diagnosis of FMD were genotyped for 18 single-nucleotide polymorphisms (SNPs) from 14 candidate genes. FMD clinical characteristics, psychiatric comorbidity and symptomatology, and childhood trauma exposure were assessed. Resting-state functional connectivity data were obtained in a subgroup of 38 patients with FMD and 38 age-matched and sex-matched healthy controls. Amygdala–frontal connectivity was analysed using a whole-brain seed-based approach.Results: Among the SNPs analysed, a tryptophan hydroxylase 2 (TPH2) gene polymorphism—G703T—significantly predicted clinical and neurocircuitry manifestations of FMD. Relative to GG homozygotes, T carriers were characterised by earlier FMD age of onset and decreased connectivity between the right amygdala and the middle frontal gyrus. Furthermore, theTPH2genotype showed a significant interaction with childhood trauma in predicting worse symptom severity.Conclusions: This is, to our knowledge, the first study showing that theTPH2genotype may modulate FMD both directly and interactively with childhood trauma. Because both this polymorphism and early-life stress alter serotonin levels, our findings support a potential molecular mechanism modulating FMD phenotype.
Addictive disorders are a major public health concern, associated with high relapse rates, significant disability and substantial mortality. Unfortunately, current interventions are only modestly effective. Preclinical studies as well as human neuroimaging studies have provided strong evidence that the observable behaviours that characterize the addiction phenotype, such as compulsive drug consumption, impaired self-control, and behavioural inflexibility, reflect underlying dysregulation and malfunction in specific neural circuits. These developments have been accompanied by advances in neuromodulation interventions, both invasive as deep brain stimulation, and non-invasive such as repetitive transcranial magnetic stimulation and transcranial direct current stimulation. These interventions appear particularly promising as they may not only allow us to probe affected brain circuits in addictive disorders, but also seem to have unique therapeutic applications to directly target and remodel impaired circuits. However, the available literature is still relatively small and sparse, and the long-term safety and efficacy of these interventions need to be confirmed. Here we review the literature on the use of neuromodulation in addictive disorders to highlight progress limitations with the aim to suggest future directions for this field.
29 October 2018 in Neuromodulation: Technology at the Neural Interface
Background: Positively reinforcing properties of alcohol are in part mediated by activation of the ventral striatum (VS). Alcohol‐induced release of endogenous opioids is thought to contribute to this response. Preclinical studies show that the opioid antagonist naltrexone (NTX) can block this cascade, but its ability to do so in treatment‐seeking alcoholics has not been examined. Our objective was to study the effects ofNTXon alcohol‐inducedVSactivation and on amygdala response to affective stimuli in treatment‐seeking alcohol‐dependent inpatients.Methods: Sixty‐three treatment‐seeking alcoholics were randomized to receiveNTX(50 mg) or placebo (PLC) daily. On Day 7, participants underwent an alcohol cue reactivity session, and craving was measured using the Penn Alcohol Craving Scale. On Day 9, participants received a saline infusion followed by an alcohol infusion and also viewed affective stimuli in a magnetic resonance scanner.Results: Irrespective of medication treatment condition, the alcohol infusion did not activate theVSin the alcohol‐dependent patients. Unexpectedly,VSactivation was greater inNTXtreated patients than in thePLCgroup.NTXtreated patients also reported increased craving in response to alcohol cue exposure, and increased subjective response to alcohol (“high” and “intoxicated”) compared toPLCsubjects. No significant effects of alcohol infusion on brain response to affective stimuli were in theNTXor PLC groups.Conclusions: Unlike previous findings in social drinkers, a moderate level of intoxication did not activate theVSin treatment‐seeking alcoholics. This is likely to reflect tolerance to the positively reinforcing properties of alcohol in this clinical population. Our findings may help explain the efficacy ofNTXto reduce heavy drinking, but not to maintain abstinence.
1 August 2021 in Neuroscience & Biobehavioral Reviews
• More recently, Functional Neurological Disorder pathophysiology has become better understood. • FND as a neurocircuitry model of disease opens possibilities for neuromodulation techniques as potential treatment tools. • Existing non-invasive brain stimulation (NIBS) studies in FND are very heterogeneous in design, which prevent us to make meaningful conclusions. • The efficacy of NIBS techniques as potential treatments for FND remain to be confirmed.